AAP
CRBP icon

Arax Advisory Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Arax Advisory Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28 Hold
3
– – ﹤0.01% 3695
2025
Q4 		$24 Sell
3
-136
-98% -$1.68K ﹤0.01% 4009
2025
Q3 		$1.76K Buy
+139
New +$1.32K ﹤0.01% 3144

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arax Advisory Partners's CRBP Position: Q1 2026 in Review

Arax Advisory Partners held its Corbus Pharmaceuticals (CRBP) position steady in Q1 2026 at 3 shares worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #3695.

Arax Advisory Partners first reported a position in CRBP in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.76K in Q3 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Arax Advisory Partners held 3 shares of Corbus Pharmaceuticals worth $28 as of Q1 2026.
  • Arax Advisory Partners left its Corbus Pharmaceuticals share count unchanged in Q1 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3695 holding.
  • Arax Advisory Partners first reported a position in Corbus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Corbus Pharmaceuticals position peaked at $1.76K in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.